Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States

4/2/2026

Proclamations

View Original

Action Summary

Investigation Findings: The Secretary of Commerce’s investigation under section 232 found that U.S. reliance on imported patented pharmaceuticals and APIs poses a national security threat, with over 50% of patented pharmaceuticals and only 15% of APIs produced domestically.
National Security Concerns: The heavy dependence on foreign production jeopardizes military and civilian healthcare, especially during emergencies or disruptions in global supply chains.
Import Adjustment Plan: The President has determined that it is necessary and appropriate to adjust imports by imposing tariffs and negotiating onshoring agreements to secure a self-sufficient domestic manufacturing base.
Tariff Structure:
- *100% ad valorem tariff* on imported patented pharmaceuticals and ingredients, as delineated in Annex I.
- *Reduced 20% tariff* for companies with approved onshoring plans (increasing to 100% after 4 years).
- *Lower tariff rates* for products from designated foreign jurisdictions (e.g., 15% for EU, Japan, Korea, Switzerland/Liechtenstein and 10% reducing to 0% for the United Kingdom under future agreements).
- *Zero tariff* for pharmaceutical products meeting criteria (orphan drugs, nuclear medicines, etc.) or companies with MFN pricing and onshoring agreements.
Negotiations and Agreements: Directs the Secretary of Commerce and the Secretary of Health and Human Services to pursue or continue negotiations on agreements with trade partners and companies, including MFN pricing and onshoring commitments, with progress updates required within 90 days.
Exemptions and Limitations:
- Generic pharmaceuticals and associated ingredients will not be subject to these tariffs.
- U.S.-origin pharmaceutical products are exempt from the imposed tariffs.
Legal and Regulatory Authority: The actions are implemented under section 232 of the Trade Expansion Act, section 604 of the Trade Act of 1974, and section 301 of title 3, with provisions for future adjustments and enforcement.
Implementation and Monitoring: Tariffs become effective on specified dates; the Secretary is empowered to monitor onshoring commitments, adjust tariff rates for non-compliance, and review the national security impact of pharmaceutical imports over time.
Trade Deal Integration: The plan includes incorporating pharmaceutical-related commitments into existing deals with the EU, Japan, Korea, Switzerland/Liechtenstein, and a future agreement with the United Kingdom.

Risks & Considerations

The recent proclamation regarding the adjustment of pharmaceutical imports emphasizes national security concerns, which could lead to significant changes in the pharmaceutical supply chain. Vanderbilt University, particularly through its Medical Center, relies heavily on a steady supply of pharmaceuticals for research and patient care, which may be disrupted by these changes.
The imposition of tariffs on imported pharmaceuticals could increase the cost of medications and affect the affordability of treatments available to patients at Vanderbilt Medical Center. This might result in financial strain on the institution as it navigates these increased costs.
Vanderbilt’s research programs are significantly funded by federal grants, including those related to healthcare and pharmaceutical research. Any reductions in these funds, as indicated by the proposed tariffs and changes in import policies, may hinder ongoing and future research initiatives.
The focus on onshoring pharmaceutical production may create opportunities for local partnerships; however, it could also lead to complexities in compliance and logistics for the university’s research and clinical operations.

Impacted Programs

Vanderbilt University Medical Center (VUMC) may face challenges in sourcing essential medications, which could directly impact patient care and research capabilities.
The School of Medicine might need to adjust its research focus or funding strategies, especially in areas heavily reliant on imported pharmaceuticals.
The Office of Sponsored Programs will likely need to reassess grant applications and funding sources in light of potential changes in federal funding related to pharmaceuticals.
Potential partnerships with pharmaceutical companies for research may shift as companies adapt to the new tariffs and onshoring requirements.

Financial Impact

The introduction of tariffs on pharmaceutical imports could lead to increased operational costs for VUMC, resulting in budget constraints that may limit the ability to offer certain services or conduct specific research.
Reduced federal funding due to changes in import policies may necessitate a reevaluation of the university’s financial planning and resource allocation.
Increased local production of pharmaceuticals could create new funding opportunities for research and development, but the transition may require initial investments that could strain budgets.
Vanderbilt may need to enhance its financial aid programs to support students in healthcare fields if costs associated with pharmaceutical education increase due to tariffs.

Relevance Score: 4 (The order presents a need for potential major changes or transformations of programs.)

Key Actions

The Office of Federal Relations should closely monitor the implications of the Presidential Proclamation adjusting imports of pharmaceuticals. This includes understanding how tariffs and onshoring agreements might affect research funding and pharmaceutical partnerships, potentially influencing Vanderbilt’s biomedical research initiatives.
Vanderbilt University Medical Center (VUMC) should prepare for potential supply chain disruptions in pharmaceutical products due to increased tariffs. Developing contingency plans for sourcing critical drugs and active pharmaceutical ingredients domestically will be vital for maintaining patient care and research integrity.
The School of Medicine should engage in discussions with pharmaceutical companies regarding their plans for onshoring production. By fostering partnerships with companies committing to U.S. production, Vanderbilt can ensure access to essential medications while also exploring collaborative research opportunities.
Vanderbilt’s Office of Research Administration should assess the impact of federal policy changes on existing research grants and funding. This includes evaluating how the new import tariffs on pharmaceuticals could affect grant allocations for ongoing medical research projects.
The Vanderbilt Center for Health Services Research should analyze the broader implications of the proclamation on public health outcomes. This research could inform strategies to address potential healthcare access issues resulting from tariffs on imported pharmaceuticals.

Opportunities

The proclamation provides an opportunity for Vanderbilt’s pharmaceutical research departments to advocate for increased investment in domestic drug production. Engaging with policymakers to highlight the importance of domestic manufacturing could align with national security goals.
Vanderbilt can leverage its expertise in public health and medicine to participate in discussions about the implications of onshoring agreements for pharmaceutical companies. This could lead to collaborative efforts in research and development that align with the university’s mission.
The School of Engineering should explore partnerships with pharmaceutical companies focused on innovative manufacturing processes. By aligning research with industry needs, Vanderbilt can enhance its role in advancing pharmaceutical technologies and manufacturing efficiencies.
There is potential for the Peabody College to engage in policy advocacy related to healthcare access, particularly for populations that might be affected by changes in pharmaceutical availability due to tariffs and import adjustments.
Engaging with community stakeholders on the implications of the proclamation can position Vanderbilt as a leader in discussions about healthcare access and pharmaceutical innovation, further solidifying its role in the health sector.

Relevance Score: 4 (The proclamation presents potential for major process changes required for Vanderbilt’s operations and partnerships due to impacts on pharmaceutical imports.)

Average Relevance Score: 3.6

Timeline for Implementation

90 days: The Secretary and the Secretary of Health and Human Services must update the President on the progress of negotiations regarding agreements to adjust pharmaceutical imports within 90 days of the proclamation.
180 days (conditional): If an agreement contemplated under section 232 is not entered into within 180 days, the President may take further actions.
July 31, 2026 / September 29, 2026: Tariffs become effective for goods entered for consumption—on or after 12:01 a.m. EDT on July 31, 2026 for companies listed in Annex III, and on September 29, 2026 for other companies.
Within 1 year: The Secretary must inform the President regarding any circumstances suggesting a need to adjust imports of generic pharmaceuticals.
April 2, 2030: For products of companies with approved onshoring plans, the 20 percent duty rate will increase to 100 percent.
Until January 20, 2029: Companies with MFN pharmaceutical pricing agreements will be subject to a zero tariff rate until this date.

Relevance Score: 2

Impacted Government Organizations

Department of Commerce: Tasked with implementing tariff agreements, negotiating onshoring commitments, and directing adjustments to imports under section 232.
Department of Health and Human Services: Engaged in negotiations regarding onshoring of pharmaceutical production and ensuring public health security.
United States Trade Representative: Involved in negotiating and implementing trade agreements linked to the adjustment of pharmaceutical imports.
U.S. Customs and Border Protection (CBP): Responsible for administering and monitoring the implementation of tariffs and ensuring compliance at the border.
Department of Homeland Security: Consulted for enforcement measures and oversight related to national security aspects of the import adjustments.
United States International Trade Commission (USITC): Consulted on potential modifications to the Harmonized Tariff Schedule to implement the proclamation’s directives.

Relevance Score: 3 (Six Federal organizations are directly impacted by the proclamation.)

Responsible Officials

Secretary of Commerce – Tasked with overseeing investigations, negotiating onshoring agreements, and managing tariff modifications as detailed in the proclamation.
Secretary of Health and Human Services – Directed to negotiate and implement agreements related to pharmaceutical imports, onshoring commitments, and pricing strategies.
Secretary of Homeland Security – Authorized to take actions, including regulatory amendments and enforcement measures, to implement the proclamation’s directives.
United States Trade Representative – Consulted to adjust tariff rates and address issues related to trade negotiations as required.
Chair of the U.S. International Trade Commission and Commissioner of U.S. Customs and Border Protection (CBP) – Responsible for determining necessary administrative changes in the HTSUS and enforcing tariff provisions.

Relevance Score: 5 (Directives affect Cabinet officials with significant authority and broad actionable impacts).